Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Stereotactic Body Radiotherapy Combined With Cadonilimab for the Treatment of Advanced Refractory Malignant Solid Tumors

NCT05915481 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT05915481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05915481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Stereotactic Body Radiotherapy Combined With Cadonilimab for the Treatment of Advanced Refractory Malignant Solid Tumors
Lead sponsor
Peking University Third Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 21, 2023
Completion date
June 21, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, efficacy, immune checkpoint inhibitor, safety, stereotactic body radiotherapy